FINE-ONE Study

The OHSU Harold Schnitzer Diabetes Center (PI: Dr. Rodica Busui, MD PhD) is one of the few academic institutions that are part of a new study (FINE-ONE). Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes.

In this study, researchers want to learn if finerenone works better than placebo in reducing the participants' kidney disease from getting worse when given in addition to standard of care (SOC) treatment. Finerenone is approved for doctors to prescribe to people with chronic kidney disease and type 2 diabetes.

This study is seeking volunteers who are over 18 years of age, have Type 1 diabetes continuously treated with insulin, and have been told by their doctor they have CKD or increased protein levels in their urine.

Key Eligibility Criteria:

• Are 18 years or older
• Have type 1 diabetes, continuously treated with insulin
• Have a HbA1c at screening less than 10%
• Have a clinical diagnosis of chronic kidney disease (or have been told by your doctor you have increased protein levels in your urine)

Duration: The participants will be in the study for up to 7.5 months. Participants will take the study treatments for 6 months. During the study, they will visit the study site at least 6 times.

If you are interested or would like more information, please contact the study coordinator Ariel Miyama at 503-830-9571 or email miyama@ohsu.edu.

OHSU IRB# 27117

Would you be interested in trying a new GLP-1 medication similar to Ozempic?

We are seeking volunteers to test a new investigational glucagon-like peptide-1 (GLP-1) medication similar to Mounjaro and Ozempic. However, this GLP-1 will be approved for Type 1 instead of Type 2 diabetics and unlike other GLP-1 medications on the market, the study drug has not been shown to cause skeletal muscle loss. The purpose of this study is to see how safe and tolerable the study drug is and to see if the study drug improves your diabetes management. This category of drugs helps regulate blood sugar, appetite and digestion. If you agree to be in the study, you may be given the study drug or a placebo (a placebo does not contain any active ingredients but looks like the study drug). Your participation in this research study will involve approximately 13 visits to the research center and will last about 25 weeks.

Compensation is $100 for each visit and potential to receive stipends totally $250.

You may be eligible to participate if you are:

• Diagnosed with type 1 diabetes for at least one year
• Age 18 to 65 years old
• Stable insulin dosing/formulation for at least 2 months
• HbA1c between 7-10%
• BMI 27 or higher
• Have not used nicotine products during the last 6 months
• Have not used in last 6 months any medication that could improve/interfere with glucose control or for weight loss

Oregon Health and Science University | Portland, Oregon
Please contact Deborah Branigan at 503-418-9070
Email: diabetesresearch@ohsu.edu

TINSAL-FISH Study

The OHSU Harold Schnitzer Diabetes Center (PI: Dr. Rodica Busui, MD PhD) is part of a multicenter trial funded by the National Institute of Health to identify new therapies that could reverse diabetic neuropathy, a very common and challenging complication of diabetes that leads to nerve damage and loss. The trial is evaluating whether fish oil, alone and in combination with salsalate, a drug approved to treat arthritis may be effective to treat diabetic peripheral neuropathy, and identify new targets that could be tested in a future trial. This study is being conducted at the University of Iowa, at the University of Michigan, and Oregon Health and Sciences University (OHSU).

Key Eligibility Criteria:

• Are 18 years or older
• Have type 2 diabetes
• Have an HbA1c at screening less than 9.5%

Duration: About 6 months.

If you are interested or would like more information, please contact the study coordinator Ariel Miyama at 503-830-9571 or email miyama@ohsu.edu.

OHSU IRB# 27479